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Abstract
The quest for novel therapeutic targets in acute myeloid leukemia (AML) is still ongoing.
One of such targets, cyclin A1, was shown to be overexpressed in AML including AML stem
cells. However, the function of cyclin A1 in AML is largely unknown, and the data on its im-
pact on patients´ survival remain controversial. Therefore, we developed a transgenic
mouse model of stem cell-directed inducible cyclin A1 overexpression and crossed these
mice with PML-RARα-knockin mice, which develop an AML M3-like phenotype. To observe
the effects of cyclin A1 loss-of-function, we also crossed PML-RARα-knockin mice to cyclin
A1-knockout mice. Neither overexpression nor loss of cyclin A1 significantly altered leuke-
mogenesis in PML-RARα-knockin mice. These findings imply that upregulation of cyclin A1
is not essential for leukemogenesis. Our data suggest that cyclin A1 does not represent a
suitable target for AML therapy.
Introduction
Cell cycle regulators are an attractive target for cancer therapy [1]. Cyclin A1 is a catalytic sub-
unit of Cyclin-dependent kinases CDK) 1 and 2 and thus contributes to the regulation of pro-
liferation [2]. It was shown to be expressed in testis and brain [3], and a knock-out of Cyclin
A1 in a mouse model lead to infertility of male mice [4] without disturbing other organs. It was
therefore thought to mainly function in meiosis.
However, we and others revealed an upregulation of cyclin A1 in AML samples [5–7] as
well as in different other cancer entities [8–12]. Although cell cycle proteins including other
CDK2-dependent regulators such as cyclin A(2) and cyclin E were expressed in AML [5,6,13],
from these candidate genes only high expression of cyclin A1 was correlated with worse overall
survival [6]. Elevated levels of cyclin A1 were especially found in samples of AML M3 patients
[5,7] that are characterized by the fusion protein PML-RARα. Previously, we found out that cy-
clin A1 is a direct transcriptional target of PML-RARα function [7]. Moreover, a transgenic
mouse model constitutively overexpressing cyclin A1 in myeloid progenitor cells under the
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control of the human cathepsin G promoter developed a myeloid disease with a low penetrance
and long latency [14]. This indicated that cyclin A1 can contribute to the induction of a leuke-
mic phenotype but that at least other cooperative events were necessary to induce a cyclin
A1-triggered leukemia. The prominent upregulation of cyclin A1 in PML-RARα-positive AML
(this paper and [5]) prompted us to investigate the function of cyclin A1 in AMLM3. We took
advantage of a previously established AMLM3-mouse model that expresses PML-RARα in the
cathepsin G gene locus as a knock-in allele and develops an AML-like phenotype with a very
high penetrance [15]. In addition, we developed a new transgenic mouse model, in which the
expression of cyclin A1 can be induced by tetracycline. We asked the question if the overex-
pression of cyclin A1 enhances leukemogenesis and whether cyclin A1 expression was neces-
sary for AML.
Materials and Methods
Expression analyses
The study was reviewed and approved by the ethics committee of the physician´s chamber of
Westfalen-Lippe and the medical faculty of the University of Muenster (2007-524-f-S and
2007-390-f-S) before the study began. AML samples were obtained from the bone marrow of
patients with acute myeloid leukemia (AML) at the time of initial diagnosis. The median blast
count was 80%. Informed written consent was obtained from all patients.
Reverse transcription and real-time quantitative RT-PCR were performed as described for
human cyclin A1 [16,17]. Published microarray data from human bone marrow and blood
cells were analyzed using the Leukemia Gene Atlas at http://www.leukemia-gene-atlas.org
[18,19]. Cells used for microarray analysis were collected from the purified fraction of mono-
nuclear cells after Ficoll density centrifugation [19].
RNA isolation from sorted murine cells was performed using RNeasy Micro Kit (Qiagen,
Hilden, Germany) according to the manufacturer’s protocol.
Establishment and analysis of cyclin A1-transgenic mice
Using the bacterial artificial chromosome BAC.E11.lacZ and its corresponding plasmid pE11.
F3.M.F, the cDNA of human cyclin A1 and luciferase as reporter gene were cloned together
with Pbi-1 representing a bidirectional tet-responsive promoter element into the pE11 [20].
This vector also contains two homologous regions corresponding with two regions on the
BAC.E11.lacZ flanking a lacZ-gene [20–22]. The construct was recombined into the BAC.E11.
lacZ and confirmed with blue-white-selection, PCR, sequencing and Southern Blot (data not
shown). One clone could be identified with the complete cDNA of human cyclin A1 and lucif-
erase. This DNA was purified with pulse-field gel electrophoresis and injected into the pronu-
cleus of fertilized zygotes of C57BL6/N mice. The founder lines were bred with the driver
mouse line SCL-tTA, which expresses the tetracycline-controlled Transcriptional Activator
(tTA) under the control of the Stem Cell Leukemia (SCL) 3’-enhancer [23,24].
In the tTA-system, the expression of human cyclin A1 can be switched off by administration
of tetracycline-hydrochloride (Sigma) as described [23]. Luciferase assays were performed fol-
lowing the manufacturer’s protocol (Promega). Retroviral transduction using an rtTA-contain-
ing vector was performed as described [25]. For Western blot analysis, peritoneal mast cells
were isolated by flushing the peritoneal cavity as described [26] from induced transgenic and
control mice. Cyclin A1 Western blots were performed as described [2].
All animal experiments in this study were carried out in strict accordance with the recom-
mendations of the institutional animal care and use committee “Landesamt fuer Natur,
Umwelt und Verbraucherschutz NRW”. This study was approved by the Institutional Animal
Cyclin A1 in Murine AML
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Care and Use Committee and of the local veterinary administration of Muenster (G15/2005,
8.87–51.04.20.09.322, and 87–51.04.2011.A005).
Mice were kept in individually ventriculated (IVC-) Typ II cages (Tecniplast GmbH, Ger-
many) in groups of five mice, in a 12-hour light/dark cycle, with room temperature at 22±2 °C
and a relative air humidity of 45–65% (see S1 File: NC3Rs ARRIVE Guidelines Checklist). All
mice were allowed free access to water and a maintenance sterile diet. All reasonable efforts
were made to ameliorate suffering, including anesthesia using isoflurane inhalation for retro-
orbital puncture and isolation of affected mice. Mice were monitored daily for signs of pain or
distress. Moribund mice were humanely sacrificed as described below. Study design and bio-
metric planning of each experiment was performed in accordance with a biostatistician. Mice
were sacrificed for sample preparation by deep anesthesia via isoflurane inhalation followed by
cervical dislocation. For each experiment, the single animal was an experimental unit.
Breeding
SCL-tTA-tg/cyclin A1-tg mice (FVB/NxC57BL6/N background) or cyclin A1+/- mice (Balb/c
background; generously provided by Mark Carrington [2]), respectively, were bred with
PML-RARα-knockin-mice (C57BL6/N background; generously provided by Timothy Ley;
[15]). Because of the different genetic backgrounds, we compared two groups of littermates of
each breeding strategy. SCL-tTA-tg/cyclin A1-tg mice breedings were kept under tetracycline-
repression. Cyclin A1 and luciferase expression was induced by withdrawal of tetracycline
from the drinking water.
Analysis of survival
Mice were stated as moribund when they showed certain signs of sickness, i.e. shivering, weight
loss, neglected grooming. Moribund animals were euthanized as described above. The results
of the survival experiments were analyzed with the log-rank non-parametric and represented
as Kaplan-Meier survival curves.
Flow cytometry and hematological analysis
Preparation of blood, bone marrow or spleen cells for staining and FACS analysis was per-
formed as described previously [25,27]. WBC and blood parameters were analyzed by using
the Hemavet multispecies hematology analyzer (Drew Scientific, UK) following the manufac-
turer´s instruction. Peripheral blood smears were stained according to the May-Grünwald
standard procedure. Colony formation assays from total primary bone marrow were carried
out essentially as described [25].
Results and Discussion
We and others identified specific upregulation of cyclin A1 in human AML samples (Fig 1A,
1B and 1C), which suggested a function of cyclin A1 in leukemogenesis. This prompted us to
analyze cyclin A1 expression in murine AML samples. Indeed, we observed striking and signifi-
cant upregulation of cyclin A1 expression only in fully developed AML-samples in
PML-RARα-knockin mice (Fig 1D) whereas non-leukemic or pre-leukemic mice did not show
increased levels of cyclin A1 in the bone marrow (Fig 1D). This indicated that PML-RARα-
knockin mice were a suitable model for the analysis of cyclin A1 upregulation in AML.
These data led to the question if ectopic cyclin A1 expression in early hematopoietic stem
cells accelerates and/or enhances leukemogenesis. Therefore, we developed an inducible cyclin
A1-expressing transgenic mouse model (Fig 2A, right-hand side) that expresses cyclin A1
Cyclin A1 in Murine AML
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(Fig 2B) as well as luciferase (Fig 2C) under the control of a bidirectional tetracycline-inducible
promoter. We crossed these mice with SCL-tTA mice, a driver mouse line that expressed the
tetracyclin-dependent transactivator in early hematopoietic stem and progenitor cells [23,24]
and induced expression of cyclin A1 (Fig 2B) by withdrawal of tetracycline. Despite this over-
expression, none of double transgenic SCL-tTA/cyclin A1 mice developed a hematopoietic dis-
ease during their life time (n = 26, data not shown). Furthermore, hematopoietic stem cell
Fig 1. Cyclin A1 expression in human andmurine leukemic blasts. A. and B. Cyclin A1 was analyzed in mRNAmicroarray expression data from the
purified fraction of human mononuclear bone marrow cells after Ficoll density centrifugation [18,19]. A. The expression of cyclin A1 was significantly
increased in AML blasts compared to normal bone marrow (NBM) (p<0.001, t-test). Shown here are log arbitrary units. B. The expression of cyclin A1 was
significantly decreased in AML blasts with complex karyotype and increased in AML M3 blasts compared with normal karyotype and (*p<0.001, t-test). C.
Cyclin A1 expression was significantly induced in bone marrow cells from human AML patients with FAB subtype M3 (p = 0.015, t-test) and with FAB subtype
M5/5a/5b (p = 0.05, two-tailed t-test) compared to normal bone marrow cells (NBM). Cyclin A1 expression was determined by qRT-PCR and normalized to
GAPDH expression level. D. In bone marrow cells of PML-RARα-knockin mice, cyclin A1 expression was significantly upregulated upon a full-blown
leukemic phenotype compared to non-leukemic PML-RARα-knockin mice (p = 0.04, t-test).
doi:10.1371/journal.pone.0129147.g001
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function was not altered, since colony formation of hematopoietic progenitor cells and the
number of hematopoietic progenitor and stem cells were not changed (data not shown). This
suggests that the AML-like phenotype observed in another transgenic mouse model depended
on time, place and the very high level of cyclin A1 expression [14] rather than representing a
specific phenomenon. It has long been known that ectopic high level expression of different on-
cogenes leads to phenotypes different from endogenous expression: For instance, the pene-
trance of PML-RARα-driven leukemia is dramatically lower when expressed as a transgene
[28] compared to expression in the endogenous gene as a knock-in [15]. Moreover, the second
known A-type cyclin, cyclin A, which is referred to as cyclin A2 in mice, is highly expressed in
bone marrow cells [29]. Conditional knockout of cyclin A2 expression in the bone marrow
leads to ablation of the hematopoietic compartment, while the additional absence of cyclin A1
in double-knockout bone marrow did not enhance this phenotype [29]. These results suggest
that cyclin A2 has very prominent functions in the bone marrow that the overexpression of cy-
clin A1 like in our model might not outperform.
We bred these SCL-tTA/cyclin A1 double transgenic mice to PML-RARαmice and followed
leukemogenesis after induction of cyclin A1 by tetracycline withdrawal. Intriguingly, no signifi-
cant change in survival (Fig 3A) or leukemia phenotype (Fig 3B) was observed, since the per-
centage of CD34+/GR-1+ leukemic blast cells was unchanged in transgenic vs control mice
bone marrow (tg: 66+/-18% compared to control: 50+/-21%; t-test: p = n.s.; n = 4 for each ge-
notype) or spleen (tg: 61+/-21% compared to control: 57+/-29%; t-test: p = n.s.; n = 4 for each
genotype). This finding suggested a limited function of cyclin A1 upregulation in the initiation
as well as in the acceleration of leukemia. The elevated expression of cyclin A1 might rather re-
sult from its upregulation by PML-RARα [7] or other AML-driving oncogenes without itself
being causative for leukemogenesis.
Although the ectopic expression of cyclin A1 in early hematopoietic cells might not acceler-
ate leukemogenesis, the inhibition or absence of cyclin A1 might preclude disease progression,
since higher levels of cyclin A1 were correlated with worse overall survival in AML patients [6].
Therefore, we crossed the PML-RARα-Knock-in mouse line with cyclin A1-knockout mice.
Strikingly, mice died by development of AML in presence or absence of cyclin A1, and there
was no difference in phenotype or latency of the disease (Fig 3C and 3D). Again, the expression
of the other A-type cyclin, cyclin A(2) might compensate for the absence of cyclin A1. Cyclin A
(2) has a prominent function in normal hematopoiesis [29] and is also expressed in AML sam-
ples [5,6]. Yet the role of cyclin A(2) in AML remains to be determined, but it is tempting to
speculate that cyclin A1 and cyclin A2 share functions in leukemic cells. The absence of cyclin
A2 lead to decreased liver tumor formation in mice [30]. Therefore, it will be very interesting
to investigate leukemogenesis in absence of both A-type cyclins.
In summary, cyclin A1 did not influence the development of murine PML-RARα-driven
AML, neither by overexpression in an endogenous setting nor by absence in a complete knock-
out model. These results can contribute to the survey for potential leukemic target genes as it
seems unlikely that cyclin A1 is an important therapy target in leukemia. On the other hand,
Fig 2. Development of a cyclin A1-transgenic mousemodel. A. Schematic overview about the constructs used to develop transgenic mouse lines. The
driver mouse line SCL-tTA expresses the tetracycline-dependent transactivator protein (tTA) in hematopoietic stem cells under the control of the stem cell
leukemia-factor enhancer [23,24]. In the novel cyclin A1-bi-luciferase responder mouse line, the cDNA of cyclin A1 and luciferase as reporter gene were
expressed in absence of tetracycline in parallel and inducibly under control of the bidirectional tTA-responsive promoter element Pbi-1. B. Bars indicate
expression levels of human cyclin A1 expression as detected by qRT-PCR in bone marrow cells that were transduced with a retroviral tTA-containing
construct and cultured with or without tetracycline in methylcellulose for 10 days (n = 2 for each sample). C. Three months old mice carrying either cyclin A1
alone (control) or together with the driver construct SCL-tTA (SCL-tTAxcyclinA1-tg; n = 3 for each genotype) were induced for seven weeks and investigated
for luciferase activity and cyclin A1 mRNA in the bone marrow and spleen. High luciferase activity was only detectable in induced SCL-tTAxcyclinA1-tg bone
marrow and spleen cells. Numbers indicate mean luciferase levels.
doi:10.1371/journal.pone.0129147.g002
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Fig 3. Cyclin A1 expression does not significantly influence PML-RARα-driven leukemogenesis. A. Kaplan-Meier survival curves of heterozygous
PML-RARα-knockin mice with (SCL-cyclinA1-tg; n = 12) or without (control; n = 14) ectopic human cyclin A1 expression in the bone marrow. Although there
was a trend towards an accelerated disease in the presence of ectopic cyclin A1 expression, latency and penetrance did not differ significantly between the
two genotypes (p = 0.282, log-rank test). Also, the phenotype of acute myeloid leukemia was not changed by the presence of cyclin A1 (B). Shown here are
examples of FACS analysis of bone marrow (upper panels) and spleen cells (lower panels) of diseased mice. Murine PML-RARα-driven leukemic blasts are
characterized by the surface expression of CD34 and GR-1 which does not occur in non-leukemic mice. The number of CD34+/GR-1+ cells in diseased mice
did not alter significantly upon cyclin A1 expression. SCL, Stem Cell Leukemia enhancer driving tTA expression [23]; FI, fluorescent intensity; P/Rα-KI,
PML-RARα-knockin mice. C. Kaplan-Meier survival curves of PML-RARα-knockin mice with wild type (PML-RARα-KI/cyclin A1+/+; n = 30) or cyclin
A1-knockout (PML-RARα-KI/cyclin A1-/-; n = 35). Cyclin A1-/- mice without PML-RARα-expression did not develop a lethal phenotype (control/cyclinA1-/-;
n = 3). Absence of murine cyclin A1 did not affect PML-RARα-driven leukemia. D. The PML-RARα-leukemic phenotype was not altered by the absence or
Cyclin A1 in Murine AML
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cyclin A1 was recently used as a new immunogenic targetable antigen [31]. Using cyclin A1 as
a tag to find leukemic cells and to target them by cytotoxic activity of cyclin A1-specific T-cell
clones might be a more promising idea than to inhibit the function of cyclin A1.
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